Literature DB >> 30176319

Etidronate-zinc Complex Ameliorated Cognitive and Synaptic Plasticity Impairments in 2-Vessel Occlusion Model Rats by Reducing Neuroinflammation.

Lina Feng1, Jing Gao1, Yuexiang Wang1, Yuen-Ki Cheong2, Guogang Ren2, Zhuo Yang3.   

Abstract

As one of the bisphosphonate derivatives, etidronate has proved to be beneficial to spatial learning and memory deficits caused by two-vessel occlusion (2-VO). In this study, the novel drug etidronate-zinc complex (Eti-Zn) was used to detect its role in synaptic plasticity and learning and memory functions in a rat model of 2-VO. Chronic cerebral hypoperfusion was induced by permanent occlusion of the common carotid artery bilaterally in adult Sprague-Dawley rats. Eti-Zn (20 mg/kg/day, tail vein injection) was administered for 7 days after a two-week operation. After treatment, a series of tests were carried out. Here, we found that Eti-Zn could reduce spatial learning and memory impairments in 2-VO model rats via the Morris water maze test. We also found that animals treated with Eti-Zn showed preference for the new-object in the novel object recognition test. In addition, the long-term potentiation and depotentiation from the Schaffer collaterals to the CA1 region in the hippocampus were enhanced by Eti-Zn treatment in 2-VO model rats. Furthermore, Eti-Zn significantly up-regulated NMDA receptor (NR) 2A, NR2B, postsynaptic density protein 95 and synaptophysin levels and prevented the destruction of dendritic spines. Moreover, Eti-Zn treatment reduced both the over-activation of microglia and the expressions of neuroinflammatory cytokines (TNF-α, IL-1β and IL-6) in the hippocampus. The increased NF-κB signaling pathway in the hippocampus of 2-VO rats was reversed after Eti-Zn treatment. In summary, these findings suggest that Eti-Zn could ameliorate the synaptic plasticity and cognitive impairments by reducing neuroinflammation in 2-VO model rats.
Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  chronic cerebral hypoperfusion; etidronate–zinc complex; learning and memory; neuroinflammation; synaptic plasticity

Mesh:

Substances:

Year:  2018        PMID: 30176319     DOI: 10.1016/j.neuroscience.2018.08.022

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Graphene Oxide Ameliorates the Cognitive Impairment Through Inhibiting PI3K/Akt/mTOR Pathway to Induce Autophagy in AD Mouse Model.

Authors:  Fangxuan Chu; Kai Li; Xiaolin Li; Lanju Xu; Jie Huang; Zhuo Yang
Journal:  Neurochem Res       Date:  2020-11-12       Impact factor: 3.996

2.  Tripchlorolide May Improve Spatial Cognition Dysfunction and Synaptic Plasticity after Chronic Cerebral Hypoperfusion.

Authors:  Zhao-Hui Yao; Xiao-Li Yao; Shao-Feng Zhang; Ji-Chang Hu; Yong Zhang
Journal:  Neural Plast       Date:  2019-02-24       Impact factor: 3.599

3.  Effect of circular RNA, mmu_circ_0000296, on neuronal apoptosis in chronic cerebral ischaemia via the miR-194-5p/Runx3/Sirt1 axis.

Authors:  Keyu Huang; Chunqing Yang; Jian Zheng; Xiaobai Liu; Jie Liu; Dongfang Che; Yixue Xue; Ping An; Di Wang; Xuelei Ruan; Bo Yu
Journal:  Cell Death Discov       Date:  2021-05-29

4.  The Minocycline Ameliorated the Synaptic Plasticity Impairment in Vascular Dementia.

Authors:  Mohammad Davood Sharifi; Narges Karimi; Mohammad Karami; Afshin Borhani Haghighi; Mohammad Shabani; Mahnaz Bayat
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

5.  GPR39 localization in the aging human brain and correlation of expression and polymorphism with vascular cognitive impairment.

Authors:  Catherine M Davis; Thierno M Bah; Wenri H Zhang; Jonathan W Nelson; Kirsti Golgotiu; Xiao Nie; Farah N Alkayed; Jennifer M Young; Randy L Woltjer; Lisa C Silbert; Marjorie R Grafe; Nabil J Alkayed
Journal:  Alzheimers Dement (N Y)       Date:  2021-10-14

Review 6.  Role of GPR39 in Neurovascular Homeostasis and Disease.

Authors:  Yifan Xu; Anthony P Barnes; Nabil J Alkayed
Journal:  Int J Mol Sci       Date:  2021-07-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.